Verapamil and digoxin are frequently used in combination, and clinical experience suggests that verapamil may increase digoxin toxicity. We have investigated the influence of verapamil on digoxin pharmacokinetics in the rat. Rats were injected with 10 mg/kg verapamil s.c. twice a day for 7 days while control rats were injected with saline only. On the 7th day, all the rats received 0.5 mg/kg of digoxin i.p. Two, 4, 6, 8 and 10 hours later, groups of 6 to 8 verapamil pretreated and control animals were sacrificed and plasma, heart, brain, liver, kidney and muscle digoxin concentrations were assayed. Digoxin levels were significantly higher in the plasma, heart, liver and muscle of the verapamil pretreated rats at 6, 8 and 10 hours (p less than 0.01).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Gastrointestinal absorption and its regulation of hawthorn leaves flavonoids.
Sci Rep
January 2025
School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, P.R. China.
Hawthorn leave flavonoids (HLF) are widely used as an herb or dietary supplements for cardio-cerebrovascular diseases. However, its gastrointestinal absorption behavior and mechanism have not been disclosed. In this study, gastrointestinal absorption and its regulation of 4''-O-glucosylvitexin (GLV), 2''-O-rhamnosylvitexin (RHV), vitexin (VIT), rutin (RUT) and hyperoside (HP) in HLF were investigated using in vitro, in situ and in vivo models.
View Article and Find Full Text PDFHigh heart rates during paroxysmal atrial fibrillation: continuous rhythm monitoring data of the RACE V study.
Heart
October 2024
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background: Preventing high heart rates in patients with atrial fibrillation (AF) is a key objective of AF management. Data regarding heart rates in patients with paroxysmal AF (PAF) is lacking. This analysis aimed to provide insight into heart rates during PAF episodes measured with continuous implantable loop monitoring.
View Article and Find Full Text PDFIncidence of All-Cause, Cardiovascular, and Atrial Fibrillation-Related Hospitalizations: Focus on Antiarrhythmic Drugs.
JACC Adv
August 2024
Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Background: Atrial fibrillation (AF) is associated with an increased risk of hospital admission, but few data on reasons for hospitalization and on the role of anti-arrhythmic drugs are available.
Objectives: The purpose of this study was to investigate the incidence rate and factors associated with all-cause, cardiovascular, and AF-related hospitalizations.
Methods: Prospective ongoing ATHERO-AF (Atherosclerosis in Atrial Fibrillation) cohort study enrolling AF patients on oral anticoagulants.
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
CPT Pharmacometrics Syst Pharmacol
April 2024
Clinical Pharmacology, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Brigatinib is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive metastatic non-small cell lung cancer. In vitro studies indicated that brigatinib is primarily metabolized by CYP2C8 and CYP3A4 and inhibits P-gp, BCRP, OCT1, MATE1, and MATE2K. Clinical drug-drug interaction (DDI) studies with the strong CYP3A inhibitor itraconazole or the strong CYP3A inducer rifampin demonstrated that CYP3A-mediated metabolism was the primary contributor to overall brigatinib clearance in humans.
View Article and Find Full Text PDFImpact of chronic obstructive pulmonary disease in patients with atrial fibrillation: an analysis from the GLORIA-AF registry.
Europace
December 2023
Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
Article Synopsis
- The study examined the relationship between chronic obstructive pulmonary disease (COPD) and atrial fibrillation (AF) using data from the global GLORIA-AF registry, focusing on how COPD affects treatment and outcomes.
- Out of 36,263 patients, 6.2% had COPD, with varying prevalence in different regions; factors like age, gender, and smoking were linked to COPD presence.
- COPD patients experienced different medication patterns and significantly worse health outcomes, including higher risks of death, major adverse cardiovascular events (MACEs), and major bleeding compared to patients without COPD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!